Pharmafile Logo

dual tasking

- PMLiVE

Good data is nothing without advocacy

In a world focused on improving outcomes, the days when drugs sold themselves on data alone have long gone. While the need for good data is indisputable, it is now...

Porterhouse Medical Group

- PMLiVE

Charity launches real-world medical cannabis study

Ex-government advisor David Nutt involved

- PMLiVE

AbbVie CEO Gonzalez defends Allergan takeover

Group's revenues will replace Humira loss

- PMLiVE

Acer Therapeutics hit by FDA filing rejection

Shares plunge as regulator calls for new trial

Trends in the Pharma Industry – A Lucid Thirsty Thursday Session

Rob Apollo, Corporate Development Director of Lucid Group, kicked off the first of a series of Thirsty Thursday sessions with a thought-provoking discussion around trends in the pharma industry and...

Lucid Group Communications Limited

My MS journey: one patient’s search for innovation

David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients.

Blue Latitude Health

- PMLiVE

Biotech profile: Tom Evans, CEO, Vaccitech.

Can UK-based company be first to develop a universal flu vaccine?

- PMLiVE

AbbVie to acquire Allergan for $63bn

Deal based on major cuts and diversified portfolio

- PMLiVE

LifeArc takes $30m equity stake in Kymab, gains access to antibody tech

Keytruda windfall helps research charity invest

- PMLiVE

Liver cancer failure dents Opdivo potential by $1bn, says analyst

Adds to bad news of forced Otezla sell-off

- PMLiVE

The social dilemma: is it time for pharma to join the party?

Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links